Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 130

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 130
---
MP compliant.

The following are summary
descriptions of our two supplier agreements to which we are a party.

Baxter Supply Agreement

On July 24, 2008, we entered
into a supply agreement, or the Supply Agreement, with Baxter Healthcare Corporation, or Baxter, and Teva Medical (Marketing) Ltd., or
Teva, which was amended and restated on January 6, 2009, pursuant to which we agreed to purchase Tisseel VHSD fibrin sealant Kit, or
Tisseel, from Teva, with Teva being Baxter’s exclusive distribution agent in Israel for Tisseel, for manufacturing of GelrinC.

<div align='center'>80</div>

The Supply Agreement had
an initial term of 3 years which ended on April 1, 2011 but has an ever-green clause and is automatically renewable for consecutive 1-year
terms (with the exception of pricing, which will be re-negotiated 90 days prior to the expiration of the term), unless either party gives
notice of termination at least 90 days prior to the then current term. The Supply Agreement may be terminated without cause by Baxter
upon 90 days’ prior written notice to the other parties. In addition, either party may terminate the Supply Agreement in the event
of a Voluntary Liquidation Event (as defined in the Supply Agreement), including, but not only, insolvency, and an uncured material breach.

Baxter Services Agreement

On February 27, 2018, we
entered into a services agreement with Baxter, or the Service Agreement, pursuant to which we agreed to purchase certain services from
Baxter in connection with Teva’s supply of Tisseel under the Agreement for manufacturing of GelrinC.

Under the Services Agreement,
Baxter provides us with quality, regulatory and technical support, for up to a maximum aggregate of 40 man-hours per year for all such
support. In consideration for receiving such support, we pay Baxter $60,000 per year until we receive FDA approval to market GelrinC
in the United States. If we exceed the 40 hours limit, Baxter will charge us $2,500 per any additional hour. Following FDA approval to
market GelrinC in the United States, we shall pay Baxter $200,000 per year during the term of this Services Agreement.

The Services Agreement has
an initial term of 5 years and is automatically renewable for consecutive 5 years term. According to the Service Agreement